Key Highlights
- India’s Sun Pharmaceutical Industries has submitted a $13 billion all-cash proposal to acquire Organon (OGN)
- The transaction would represent Sun Pharma’s biggest acquisition to date, backed by financing from JP Morgan, MUFG, and Citi
- OGN shares climbed approximately 25% during Friday’s trading session, building on a 20% year-to-date advance
- German firm Grünenthal and Swedish private equity player EQT have submitted rival bids for the healthcare company
- The latest proposal represents an increase from Sun Pharma’s earlier $12 billion approach made weeks ago
Shares of Organon (OGN) experienced a dramatic rally exceeding 25% Friday following disclosure that Sun Pharmaceutical Industries of India is advancing a $13 billion all-cash acquisition proposal for the women’s healthcare specialist.
The Economic Times broke the story Thursday evening, referencing sources with knowledge of the discussions. OGN climbed approximately 8% during afterhours trading before amplifying those advances throughout Friday’s regular session.
When the initial disclosure surfaced, Organon carried a market capitalization of merely $2.2 billion. A $13 billion proposal would deliver a substantial premium compared to recent trading levels.
The transaction, should it close, would mark Sun Pharma’s most significant acquisition in company history. The all-cash structure comes with complete financing arranged through JP Morgan, MUFG, and Citi.
Sun Pharma intends to integrate Organon into its current organizational structure. The Indian pharmaceutical company would conduct the deal entirely in cash rather than through equity issuance to existing Organon shareholders.
This represents Sun Pharma’s second approach for the target. Earlier in the month, the Mumbai-based pharmaceutical manufacturer reportedly submitted a $12 billion proposal. The newly disclosed $13 billion offer shows an escalation of $1 billion within a short timeframe.
Competition Among Multiple Suitors
Sun Pharma faces competition in its pursuit of Organon. Germany’s Grünenthal pharmaceutical company and Sweden’s EQT private equity firm have both submitted rival proposals for the business.
The competitive dynamic highlights the attractiveness of Organon’s product lineup — an extensive collection of medications and therapies concentrated primarily on women’s health, combined with its domestic manufacturing capabilities in the United States.
Organon emerged as an independent entity through a Merck spinoff completed in June 2021. The shares have experienced volatility since separation, declining nearly 30% over the trailing twelve months despite Friday’s substantial upward movement.
Exceptional Trading Activity
The acquisition reports sparked intense investor interest. Approximately 5.2 million OGN shares traded hands within the opening hours Friday morning — nearly equaling the entire three-month average daily volume of 5.9 million shares in just the initial trading period.
Friday’s 25.47% increase elevated the stock’s year-to-date performance to a 20.25% gain.
OGN traded above $9.20 per share during Thursday’s afterhours session, rising from its relatively compressed market capitalization of $2.2 billion at Thursday’s regular session close.
Neither Sun Pharma nor Organon had issued official statements confirming any transaction as of Friday afternoon.
